Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?

ABSTRACT

Defining mechanisms of resistance to hypomethylating agents (HMAs) and biomarkers predictive of treatment response remains challenging in myelodysplastic neoplasm (MDS). Currently available prognostic tools that predict overall survival and transformation to acute myeloid leukaemia have not been powered to predict responses to HMAs. Noguera-Castells et al. comprehensively characterized the epigenomic profile in patients with MDS treated with azacitidine and described a methylation signature-based prognostic tool in predicting responses to azacitidine. Commentary on Noguera-Castells et al. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine a multicentre retrospective study. Br J Haematol 2024;2041838-1843.